-+ 0.00%
-+ 0.00%
-+ 0.00%

Evotec, Bristol Myers Squibb Protein Degradation Partnership Receives Second FDA Investigational New Drug Acceptance For CELMoD Candidate, Phase 1 Expected In 2027

Benzinga·11/19/2026 07:25:23
Listen to the news
  • FDA clearance expands partnered molecular glue pipeline
  • Achievement underscores productivity of the collaboration in molecular glue discovery and potential to address patient populations with high unmet need